Why is DexCom, Inc. ?
- Healthy long term growth as Net Sales has grown by an annual rate of 19.33% and Operating profit at 24.94%
- Company has a low Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Capital Employed (avg) of 28.12% signifying high profitability per unit of total capital (equity and debt)
- The company has declared positive results in Jan 70 after 2 consecutive negative quarters
- OPERATING CASH FLOW(Y) Highest at USD 1,440.7 MM
- ROCE(HY) Highest at 34.5%
- INTEREST COVERAGE RATIO(Q) Highest at 9,242.86
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -11.58%, its profits have risen by 45.1% ; the PEG ratio of the company is 0.7
How much should you buy?
- Overall Portfolio exposure to DexCom, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is DexCom, Inc. for you?
High Risk, Low Return
Quality key factors
Valuation Key Factors 
Technical key factors
Technical Movement
Highest at USD 1,440.7 MM
Highest at 34.5%
Highest at 9,242.86
Fallen by -6.96% (YoY
Lowest at -22.18 %
Highest at 3.15 times
Highest at USD 1,259.6 MM
Highest at USD 388.2 MM
Highest at 30.82 %
At USD 340.7 MM has Grown at 61.24%
At USD 267.3 MM has Grown at 76.2%
Here's what is working for DexCom, Inc.
Operating Cash Flows (USD MM)
Operating Profit to Interest
Net Sales (USD MM)
Operating Profit (USD MM)
Operating Profit to Sales
Pre-Tax Profit (USD MM)
Net Profit (USD MM)
Debt-Equity Ratio
Inventory Turnover Ratio
Raw Material Cost as a percentage of Sales
Depreciation (USD MM)






